Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3DHWE)

• Drug Name: SAR442970 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Inflammation	1A00-CA43.1	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM3DHWE

Molecule-Related Drug Atlas

Drug(s) Targeting Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[2]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[3]
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[4]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[5]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[6]
Golimumab	DMHZV7X	Psoriatic arthritis	FA21	Approved	[7]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[8]
Etanercept	DMCV109	Arthritis	FA20	Approved	[9]
Adalimumab	DMQMV1B	Crohn disease	DD70	Approved	[10]
Infliximab	DMH7OIA	Crohn disease	DD70	Approved	[11]

Drug(s) Targeting TAX transcriptionally-activated glycoprotein 1 (OX40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[12]
RG7888	DM2SWI8	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
Amlitelimab	DMKR3BQ	Asthma	CA23	Phase 2	[14]
mRNA-2752	DMUKBI2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
MEDI6383	DM1YSMD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
mRNA-2416	DMFTAWU	Lymphoma	2A80-2A86	Phase 1	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TAX transcriptionally-activated glycoprotein 1 (OX40)	TTBW580	TNFL4_HUMAN	Not Available	[1]
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of Sanofi
• [2] Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
• [3] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [4] Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
• [5] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
• [6] Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
• [7] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [8] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [9] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [10] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
• [11] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
• [12] Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68.
• [13] Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105.
• [14] OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics. 2022 Dec 8;14(12):2753.
• [15] Clinical pipeline report, company report or official report of Moderna Therapeutics.
• [16] J Clin Oncol 33, 2015 (suppl; abstr 3056).
• [17] Clinical pipeline report, company report or official report of Moderna Therapeutics.